{"disease":{"id":"post-polycythaemia-vera-myelofibrosis","name":"Post-polycythaemia vera myelofibrosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"fedratinib-hydrochloride","indication_name":"Post-polycythaemia vera myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB HYDROCHLORIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"JAK2, FLT3","drug_class":"","quality_score":62,"revenue":null,"mechanism":"Fedratinib inhibits JAK2 and FLT3 kinases, reducing STAT3/5 phosphorylation and cell proliferation in MPNs."},{"drug_id":"fedratinib","indication_name":"Post-polycythaemia vera myelofibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inrebic","generic_name":"FEDRATINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cyclin-G-associated kinase","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Inrebic works by blocking the activity of Cyclin-G-associated kinase, a protein involved in the proliferation and survival of bone marrow cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}